Uploaded November 2026 | Updated November 2026, 3 days ago
The U.S. Food and Drug Administration now requires all weight loss drugs to carry a warning label about a potential increased risk of sudden blindness, according to new guidance from the agency.
Experts say the condition is known as non-arteritic anterior ischemic optic neuropathy, or as NAION, and it comes out of nowhere.|
Micaela Marshall reports: azfamily.com/2026/11/10/fda-requires-blindness-warning-label-glp-1-drugs
For more Local News from KPHO: azfamily.com
For more YouTube Content: youtube.com/channel/UCIrgpHvUm1FMtv-C1xwkJtw
The U.S. Food and Drug Administration now requires all weight loss drugs to carry a warning label about a potential increased risk of sudden blindness, according to new guidance from the agency.
Experts say the condition is known as non-arteritic anterior ischemic optic neuropathy, or as NAION, and it comes out of nowhere.|
Micaela Marshall reports: azfamily.com/2026/11/10/fda-requires-blindness-warning-label-glp-1-drugs
For more Local News from KPHO: azfamily.com
For more YouTube Content: youtube.com/channel/UCIrgpHvUm1FMtv-C1xwkJtw










